Trial
NCT06219174
Targeting ODC as an Immunotherapeutic Target in STK11 (LKB1) Pathway-Deficient NSCLC (DFMO)
Phase ISUSPENDEDOTHER/UNKNOWNConfidence: LOW
Sponsor
H. Lee Moffitt Cancer Center and Research Institute
Collaborators
—
Condition
Non Small Cell Lung Cancer
Intervention
Pembrolizumab
Why stopped
Drugs unavailable
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-03-06